Skip to content
10-Q

Quarterly Report

Nuo Therapeutics, Inc. AURX

0001437749-24-034325

← back to feed
Filed
Nov 12, 2024 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2024 · Nov 11, 2024 46.6M sh
Cash And Equivalents Q3 2024 · Sep 30, 2024 $683.84K
Cash And Equivalents Q3 2024 · Dec 31, 2023 $928.68K
Cash And Equivalents Q3 2024 · Sep 30, 2023 $582.59K
Cash And Equivalents Q3 2024 · Dec 31, 2022 $2.05M
Current Liabilities Q3 2024 · Sep 30, 2024 $714.03K
Current Liabilities Q3 2024 · Dec 31, 2023 $674.53K
Total Liabilities Q3 2024 · Sep 30, 2024 $828.72K
Total Liabilities Q3 2024 · Dec 31, 2023 $838.73K
Current Assets Q3 2024 · Sep 30, 2024 $1.34M
Current Assets Q3 2024 · Dec 31, 2023 $1.56M
Total Assets Q3 2024 · Sep 30, 2024 $1.72M
Total Assets Q3 2024 · Dec 31, 2023 $1.88M
Capex Q3 2024 · Sep 30, 2023 $7.24K
Operating Cash Flow Q3 2024 · Sep 30, 2023 −$2.5M
Stockholders Equity Q3 2024 · Sep 30, 2023 $726.72K
Stockholders Equity Q3 2024 · Jun 30, 2023 $470.84K
Stockholders Equity Q3 2024 · Mar 31, 2023 $1.34M
Stockholders Equity Q3 2024 · Dec 31, 2022 $2.19M
Eps Basic Q3 2024 · Sep 30, 2023 −$0.02
Eps Basic Q3 2024 · Sep 30, 2023 −$0.06
Sga Expense Q3 2024 · Sep 30, 2023 $967.98K
Sga Expense Q3 2024 · Sep 30, 2023 $2.84M
Net Income Q3 2024 · Sep 30, 2023 −$790.64K
Net Income Q3 2024 · Sep 30, 2023 −$2.52M
Net Income Q3 2024 · Jun 30, 2023 −$871.89K
Net Income Q3 2024 · Mar 31, 2023 −$855.76K
Operating Income restated Q3 2024 · Sep 30, 2023 −$789.55K
Operating Income Q3 2024 · Sep 30, 2023 −$2.52M
Gross Profit Q3 2024 · Sep 30, 2023 $178.42K
Gross Profit Q3 2024 · Sep 30, 2023 $326.79K